Drawing for MEDILOX

USPTO serial 79298414

MEDILOX

Reviewed by CopyMark Law Group

Reg. 6585404Status 700Renewal
Filing date
Status date
Registration date
Dec 14, 2021
Examiner
BLAZICH, JOAN MICHELE
Law office
PUBLICATION AND ISSUE SECTION

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with MEDILOX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $399*

Plus Government fees of $325

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Benjamin M. Cantor

Benjamin M. Cantor Cantor Colburn LLP20 Church Street22nd FloorHartford, CT 06103

Goods and services

ClassDescriptionStatusFirst use
005Fungicides for domestic use; sanitizing preparations for hospital use; fungicides; sanitary sterilising preparations; fungicides for medical use; antiseptics with prophylactic effect; all purpose disinfectants; disinfectants for medical instrumentsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 6, 2023NREPNEW REPRESENTATIVE AT IB RECEIVED—
Jun 21, 2022FINVFINAL DECISION TRANSACTION PROCESSED BY IB—
May 27, 2022FICSFINAL DISPOSITION NOTICE SENT TO IB—
May 27, 2022FIMPFINAL DISPOSITION PROCESSED—
Mar 14, 2022FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Dec 14, 2021R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 28, 2021NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 28, 2021PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 8, 2021NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Aug 26, 2021ALIEASSIGNED TO LIE—
Aug 26, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 25, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 25, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 25, 2021TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 22, 2021RFNTREFUSAL PROCESSED BY IB—
Mar 1, 2021RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Mar 1, 2021RFRRREFUSAL PROCESSED BY MPU—
Feb 23, 2021RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Feb 22, 2021CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 20, 2021DOCKASSIGNED TO EXAMINER—
Dec 4, 2020MAFRAPPLICATION FILING RECEIPT MAILED—
Nov 30, 2020NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Nov 26, 2020REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance